Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

PURPOSE: Irinotecan plus cisplatin (IP) improved survival over etoposide plus cisplatin (EP) in Japanese patients with extensive-stage small-cell lung cancer (E-SCLC). To confirm those results and discern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a larg...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lara, Primo N., Natale, Ronald, Crowley, John, Lenz, Heinz Josef, Redman, Mary W., Carleton, Jane E., Jett, James, Langer, Corey J., Kuebler, J. Philip, Dakhil, Shaker R., Chansky, Kari, Gandara, David R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2684855/
https://ncbi.nlm.nih.gov/pubmed/19349543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.1061
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados